We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.
- Authors
Yates, Thomas; Sargeant, Jack A.; King, James A.; Henson, Joe; Edwardson, Charlotte L.; Redman, Emma; Gulsin, Gaurav S.; Brady, Emer M.; Ahmad, Ehtasham; Stensel, David J.; Webb, David R.; McCann, Gerry P.; Khunti, Kamlesh; Davies, Melanie J.
- Abstract
<bold>Objective: </bold>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown.<bold>Research Design and Methods: </bold>We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity.<bold>Results: </bold>Liraglutide (mean -1,144 steps/day; 95% CI -2,069 to -220), empagliflozin (-1,132 steps/day; -1,739, -524), and sitagliptin (-852 steps/day; -1,625, -78) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate- to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity.<bold>Conclusions: </bold>The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.
- Subjects
PHYSICAL activity; SODIUM-glucose cotransporter 2 inhibitors; GLUCAGON-like peptide 1; CD26 antigen; PEPTIDE receptors
- Publication
Diabetes Care, 2022, Vol 45, Issue 11, p2749
- ISSN
0149-5992
- Publication type
journal article
- DOI
10.2337/dc22-0888